Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Weihua Zhi"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThis study aimed to assess the effectiveness and safety of vascular intervention combined with lenvatinib versus vascular intervention alone in the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT),
Externí odkaz:
https://doaj.org/article/cf9afd8088554c75b18d5af18a3e1af3
Autor:
Yue Han, Guang Cao, Bin Sun, Jian Wang, Dong Yan, Haifeng Xu, Qinsheng Shi, Zechuan Liu, Weihua Zhi, Liang Xu, Bojun Liu, Yinghua Zou
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC). This study aimed to explore the bene
Externí odkaz:
https://doaj.org/article/2c62206c6c4d42cab4f8ff8141c8fb51
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposeTo retrospectively evaluate the safety and efficacy of percutaneous computed tomography (CT)-guided microwave ablation (MWA) in colorectal cancer (CRC) lung metastases, and to analyze prognostic factors.Materials and methodsData were collected
Externí odkaz:
https://doaj.org/article/e743fe234393476cbee3277bc9155d24
Autor:
Weihua Zhi, Qiang Jiang
Publikováno v:
Third International Conference on Artificial Intelligence and Computer Engineering (ICAICE 2022).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53e3762c1b5327ec12bd2e33e1e47fd2
https://doi.org/10.1117/12.2671233
https://doi.org/10.1117/12.2671233
Publikováno v:
Oncologie. 24:101-111
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85b40b1a2a06a6aa3844a26ac15df2b0
https://doi.org/10.32604/oncologie.2022.020357
https://doi.org/10.32604/oncologie.2022.020357
Autor:
Yinghua Zou, Qinsheng Shi, Bin Sun, Weihua Zhi, Haifeng Xu, Yue Han, Zechuan Liu, Jing Wang, Liang Xu, Dong Yan, Guang Cao, Bojun Liu
Publikováno v:
BMC Gastroenterology
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-10 (2021)
Background The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC). This study aimed to explore the benefits and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6aa15c7593d4cf2042ec31fb2c3f994
https://pubmed.ncbi.nlm.nih.gov/34670512
https://pubmed.ncbi.nlm.nih.gov/34670512
Publikováno v:
Journal of Cancer Research and Therapeutics. 18:1346
Hepatocellular carcinoma (HCC) is one of the most common malignant cancers worldwide. Less than 30% of patients are suitable candidates for surgery. Transarterial chemoembolization (TACE) is considered as a first-line treatment for patients with unre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f4b04a0513cd082845b0676908970a7
https://doi.org/10.4103/jcrt.jcrt_732_22
https://doi.org/10.4103/jcrt.jcrt_732_22